The Bacteriocin Nisin, an Effective Agent for the Treatment of Staphylococcal Mastitis During Lactation
Departamento de Nutrición, Bromatología y Tecnología de los Alimentos (NBTA), Universidad Complutense de Madrid (UCM), Spain. Journal of Human Lactation
(Impact Factor: 1.99).
09/2008; 24(3):311-6. DOI: 10.1177/0890334408317435
Eight women with clinical signs of staphylococcal mastitis were randomly divided in 2 groups. A solution of the bacteriocin nisin (6 microg/mL) was applied to the nipple and mammary areola of those assigned to the nisin group for 2 weeks, and a similar preparation devoid of nisin was applied to the control group. On day 0, staphylococcal counts in breast milk of the nisin and control groups were similar (5.04+/-0.19 and 4.88+/-0.21 log10 CFU/mL, respectively). However, on day 14, the mean in the nisin group (3.22+/-0.43 log10 CFU/mL) was statistically lower than that of the control group (5.01+/-0.21 log10 CFU/mL). No clinical signs of mastitis were observed among the women of the nisin group on day 14, whereas they persisted throughout the study in the women of the control group. In conclusion, nisin seems to be an efficient alternative to antibiotics for the treatment of staphylococcal mastitis.
Available from: Bayer A. Edward
- "Conversely, when the bacteriocin was used in complex with phosphatidylcholine–cardiolipin liposomes it was able to inhibit mycobacterium within the cells and to prolong the life of infected mice (Sosunov et al., 2007). An in vivo study concerning women affected by staphylococcal mastitis demonstrated that the use of a nisin-containing solution on the infected area for two weeks significantly decreased staphylococcal counts and mastitis symptoms (Fernandez et al., 2008). Mutacin B-Ny266 from the Str. "
[Show abstract] [Hide abstract]
ABSTRACT: Lactic acid bacteria (LAB) have long been used in industrial applications mainly as starters for food fermentation or as biocontrol agents or as probiotics. However, LAB possess several characteristics that render them among the most promising candidates for use in future biorefineries in converting plant-derived biomass – either from dedicated crops or from municipal/industrial solid wastes – into biofuels and high value-added products. Lactic acid, their main fermentation product, is an attractive building block extensively used by the chemical industry, owing to the potential for production of polylactides as biodegradable and biocompatible plastic alternative to polymers derived from petrochemicals. LA is but one of many high-value compounds which can be produced by LAB fermentation, which also include biofuels such as ethanol and butanol, biodegradable plastic polymers, exopolysaccharides, antimicrobial agents, health-promoting substances and nutraceuticals. Furthermore, several LAB strains have ascertained probiotic properties, and their biomass can be considered a high-value product. The present contribution aims to provide an extensive overview of the main industrial applications of LAB and future perspectives concerning their utilization in biorefineries. Strategies will be described in detail for developing LAB strains with broader substrate metabolic capacity for fermentation of cheaper biomass.
Biotechnology Advances 08/2014; 32(7). DOI:10.1016/j.biotechadv.2014.07.005 · 9.02 Impact Factor
Available from: Des Field
- "However, further animaltrial-based investigations are required to confirm the efficacy of these peptides. From a human medicine perspective , the potential of Nisin in treating infectious mastitis in lactating mothers has already been demonstrated (Fernandez et al., 2008). Significantly, Nisin prepared from the Nis+ strain L. lactis ESI 515 effectively reduced staphylococcal numbers in breast milk and led to the complete disappearance of clinical signs of mastitis after 2 weeks of treatment. "
[Show abstract] [Hide abstract]
ABSTRACT: Nisin A is the most thoroughly investigated member of the lantibiotic family of antimicrobial peptides. In addition to a long history of safe use as a food antimicrobial, its activity against multi-drug resistant pathogens has resulted in a renewed interest in applying nisin as a chemotherapeutic to treat bacterial infections. The wealth of Nisin-related information that has been generated has also led to the development of the biotechnological capacity to engineer novel Nisin variants with a view to improving the function and physicochemical properties of this already potent peptide. However, the identification of bioengineered Nisin derivatives with enhanced antimicrobial activity against Gram-positive targets is a recent event. In this study, we created stable producers of the most promising derivatives of Nisin A generated to date [M21V (hereafter Nisin V) and K22T (hereafter Nisin T)] and assessed their potency against a range of drug-resistant clinical, veterinary and food pathogens. Nisin T exhibited increased activity against all veterinary isolates, including streptococci and staphylococci, and against a number of multi-drug resistant clinical isolates including MRSA, but not vancomycin-resistant enterococci. In contrast, Nisin V displayed increased potency against all targets tested including hVISA strains and the hyper-virulent Clostridium difficile ribotype 027 and against important food pathogens such as Listeria monocytogenes and Bacillus cereus. Significantly, this enhanced activity was validated in a model food system against L. monocytogenes. We conclude that Nisin V possesses significant potential as a novel preservative or chemotherapeutic compound.
Microbial Biotechnology 07/2010; 3(4):473-86. DOI:10.1111/j.1751-7915.2010.00184.x · 3.21 Impact Factor
Available from: Antonio Maldonado-Barragán
- "In fact, some of the lactic acid bacteria strains isolated from this biological fluid have the ability to inhibit the growth of a wide spectrum of pathogenic bacteria by competitive exclusion and ⁄ or through the production of antimicrobial compounds, such as bacteriocins , organic acids or hydrogen peroxide (Beasley and Saris 2004; Martín et al. 2005, 2006; Olivares et al. 2006; Fernández et al. 2008). "
[Show abstract] [Hide abstract]
ABSTRACT: Breast milk has been described as a source of bacteria influencing the development of the infant gut microbiota. Up to the present, few studies have been focused on the application of culture-independent techniques to study bacterial diversity in breast milk. In this context, the aim of this study was to characterize the breast milk microbiota of healthy women by applying the quantitative real-time PCR technique (qRTi-PCR).
A total of 50 breast milk samples were analysed by qPCR to assess the presence of different bacterial genera or clusters, including the Bifidobacterium, Lactobacillus, Staphylococcus, Bacteroides, Enterococcus, Streptococcus, Clostridium cluster IV and Clostridium cluster XIVa-XIVb groups. Staphylococcus, Streptococcus, Bifidobacterium and Lactobacillus were the predominant groups and were detected in all the samples. Clostridium XIVa-XIVb and Enterococcus were detected in most of the samples in contrast to the Bacteroides and Clostridium cluster IV groups.
Our results confirm the abundance of bacterial DNA in breast milk samples and suggest that the qRTi-PCR technique has a huge potential in the microbiological analysis of human milk.
qRTi-PCR allowed the detection of bacterial DNA of streptococci, staphylococci, lactic acid bacteria and bifidobacteria in the samples of human milk, which confirms that breast milk can be an important source of bacteria and bacterial DNA to the infant gut.
Letters in Applied Microbiology 03/2009; 48(5):523-8. DOI:10.1111/j.1472-765X.2009.02567.x · 1.66 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.